Lung Cancer with Brain Metastases Treated with Radiotherapy Followed by Bevacizumab Maintenance: A Case Report

Authors

  • Sajjad Ahmed Khan Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal
  • Sakshyam Gautam Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal
  • Sulav Sapkota Department of Medical Oncology, Birat Medical College Teaching Hospital, Biratnagar, Morang, Nepal

DOI:

https://doi.org/10.31729/jnma.7400

Keywords:

bevacizumab; brain metastases; radiotherapy.

Abstract

Brain metastases in a patient with non-small cell lung cancer carry a grave prognosis. Without effective interventions, the average survival rate is 6 months. Here, we present a case of a 59-year-old male with non-small cell lung cancer and multiple brain metastases treated with radiotherapy followed by bevacizumab maintenance with prolonged survival. There are limited studies establishing the efficiency and toxicity profile of anti-vascular endothelial growth factors for brain metastases. This reported case had a remarkable response with marked clinical and radiological improvement along with a tolerable toxicity profile. Showing the extent of effectiveness and efficacy of anti-vascular endothelial growth factor agents in the case of lung cancer with brain metastases is the main motto of our study.

Downloads

Published

2022-06-01

How to Cite

Khan, S. A. ., Gautam, S. ., & Sapkota, S. . (2022). Lung Cancer with Brain Metastases Treated with Radiotherapy Followed by Bevacizumab Maintenance: A Case Report. Journal of Nepal Medical Association, 60(250), 569–572. https://doi.org/10.31729/jnma.7400

Issue

Vol. 60 No. 250 (2022): JNMA: Published Monthly

Section

Case Reports

License

Copyright (c) 2022 Sajjad Ahmed Khan, Sakshyam Gautam, Sulav Sapkota

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

JNMA allow to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose. The author(s) are allowed to retain publishing rights without restrictions. The JNMA work is licensed under a Creative Commons Attribution 4.0 International License. More about Copyright Policy.